anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention discloses a modifier for a gelatinase A inhibitory polypeptide and a preparation method thereof. The molecular weight of the modifier for a gelatinase A inhibitory polypeptide is 11000-13000. The preparation method comprises the following steps: respectively weighing M205C4 and mPEG-SC in a mol ratio of 1:(1-5), and dissolving the M205C4 and mPEG-SC in a PBS (phosphate buffer solution) of which the pH value is 5.0-8.0, wherein the reaction concentration of the M205C4 is 100 mu M; reacting at 4 DEG C for 3 hours on a mute mixer to obtain an M205C4-PEG mixed solution; and carrying out liquid-phase separation on the mixed solution, and purifying to obtain freeze-dried powder. The modifier for a gelatinase A inhibitory polypeptide overcomes the defects of low stability and high in-vivo metabolism velocity in the M205C4 active peptide, and has the advantages of high activity, high stability, long half life and the like. The PEG has the advantages of great varieties and wide sources; the modification method is simple and easy to implement; and the modified product is stable, and easy to store. By selecting the variety and size of the PEG, the modified product M205C4-PEG, which has the advantages of high activity, high stability and long half life, is obtained, thereby providing important foundation for application of the M205C4-PEG in in-vivo treatment.
To participate in the study the subjects must be at least 18 years old and give a written informed consent after an oral and written explanation of the study aims and methods. The study sample will include the female and male patients with panic disorder or major depression diagnosis according to DSM-IV criteria. Patients will be recruited from the out- and inpatients services of the Psychiatric Clinic of the Tartu University Hospital. For the detailed assessment of clinical severity of specific disorder and treatment effects the disorder-specific rating scales: Montgomery-Asberg's Depression Rating Scale (MADRS), Clinical Global Impression scale (CGI) will be used. The adverse effects will be evaluated by letting the patients to fill the checklist of side-symptoms. In both patient groups (with panic disorder and major depression) an SSRI escitalopram (Cipralex) will be administrated for 12 weeks in flexible dose ranging between 10 - 20 mg/per day. At the end of week 12 the patients will defined as responders if the decrease in MADRS scores is at least 50% and score on the CGI improvement scale is 2 or less. The remitters will defined if the scores are less than 12 on the MADRS. Patients who do not meet these criteria will defined as non-responders and non-remitters respectively. Depressive patients, showing non-response to escitalopram monotherapy will given the combination of 20 mg of escitalopram and 150-300 mg of bupropion (Wellbutrin SR) for 6 weeks.
As reported in the literature, cocaine hydrochloride causes an increase in observed blood pressure and heart rate. In the Phase 3 clinical studies with NUMBRINO, increases in blood pressure and heart rate were observed following pledget removal. Monitor for changes in vital signs, including heart rate and rhythm, after administration of NUMBRINO.

Avoid use of NUMBRINO in patients with a history of myocardial infarction, coronary artery disease, congestive heart failure, irregular heart rhythm, abnormal ECG, or uncontrolled hypertension. Avoid use of additional vasoconstrictor agents such as epinephrine or phenylephrine with NUMBRINO. If concomitant use is unavoidable, prolonged vital sign and ECG monitoring may be required. 

Although not reported in the NUMBRINO clinical trials, myocardial infarction has been reported in the literature, and can occur when the drug has been used as recommended [see Adverse Reactions (6)].
BACKGROUND: There is little consensus on how to make a diagnosis announcement of severe chronic disease in neurology. Other medical specialties, such as oncology, have developed assessment methods similar to the Objective Structured Clinical Examination (OSCE) to address this issue. Here we report the implementation of an OSCE focused on the diagnosis announcement of chronic disease in neurology by residents.
OBJECTIVE: We aimed to evaluate the acceptability, feasibility and validity in routine practice of an OSCE combined with a theoretical course focused on diagnosis announcement in neurology.
METHOD: Eighteen neurology residents were prospectively included between 2019 and 2022. First, they answered a questionnaire on their previous level of training in diagnosis announcement. Second, in a practical session with a simulated patient, they made a 15-min diagnosis announcement and then had 5mins of immediate feedback with an expert observer, present in the room. The OSCE consisted of 4 different stations, with standardized scenarios dedicated to the announcement of multiple sclerosis (MS), Parkinson's disease (PD), Alzheimer's disease (AD) and amyotrophic lateral sclerosis (ALS). Third, in a theory session, expert observers covered the essential theoretical points. All residents and expert observers completed an evaluation of the "practical session" and the "theory session".
RESULTS: Residents estimated their previous level of diagnosis announcement training at 3.1/5. The most feared announcements were AD and ALS. The "practical session" was rated at a mean of 4.1/5 by the residents and 4.8/5 by the expert observers, and the "theory session" at a mean of 4.7/5 by the residents and 5/5 by the expert observers. After the OSCEs, 11 residents felt more confident about making an announcement.
CONCLUSION: This study has shown a benefit of using an OSCE to learn how to make a diagnosis announcement of severe chronic disease in neurology. OSCEs could be used in many departments in routine practice and seem adapted to residents.
A pharmaceutical composition for oral administration of potassium salt in a form not irritating to the gastrointestinal mucosa comprises tablets or capsules of micropellets of a potassium salt, such as potassium chloride. The micropellets are coated with a permeable polymer comprising a low viscosity (10cp.) ethylcellulose in combination with triacetin. This coating provides a strong film resistant to breakage during formation of tablets and filling of capsules. The protective coating of the micropellets prevents the early release of potassium ions, while the tablet or capsule disintegrates and the micropellets are dispersed within the lumen of the gastrointestinal tract. As water passes through the permeable but insoluble coating, potassium ions are gradually eluted into the fluid of the tract over a period of many hours, thereby allowing time for the ions to be absorbed from the tract before high, irritating ion concentrations can form.
Active treatment group: each patient will be given 3 treatment sessions per week for 4 weeks (a total of 12 sessions). Each session is 20 minutes long and will be consisted of 20Hz stimulation trains (active) over the motor cortex and the prefrontal cortex.
A surgical instrument including a jaw assembly is disclosed. The surgical instrument further includes a motor-driven drive system configured to manipulate the jaw assembly. The surgical instrument further includes a control system configured to control the drive system and also to control a power supply system configured to supply electrical power to electrodes defined at the jaw assembly. In use, the surgical instrument may be used to apply the mechanical and electrical energy to tissue of a patient simultaneously or at different times. In certain embodiments, the user controls when mechanical and electrical energy is applied. In some embodiments, the control system controls when the mechanical and electrical energy is applied.
The invention provides a processing method and an application for yeast black tea. The method comprises the following steps: Saccharomyces Candidasp. and water are prepared into dampening solution according to the mass proportion of 1:200 to 700, the dampening solution is sprayed on tea leaves so as to lead the Saccharomyces Candidasp. to be uniformly distributed on the tea leaves, and the water content is 18 to 26% after the tea leaves are dampened; the tea leaves are put into a stainless steel fermentation tank for compressing fermentation, the fermentation temperature is within 22 to 45 DEG C, the relative humidity of air is within 80 to 90%, and the fermentation time is within 5 to 10 days; and then the yeast black tea is obtained after fermentation. Compared with the present green tea, black tea, oolong tea, yellow tea, white tea and post-fermented tea, the invention utilizes the fermentation capability of the microorganism Saccharomyces Candidasp. to greatly reduce the contents of caffeine, theophylline and esterified catechin in the tea leaves, thereby leading the yeast black tea not to stimulate a gastrointestinal system and affect the sleeping; moreover, the yeast black tea is sweet and nearly not bitter, so as to be suitable for the requirements of most people for the taste. With obvious antioxidant activity and antibacterial function, the yeast black tea not only can be used as raw materials for special cosmetics and natural medicine, but also can be used for a food additive in the food processing industry.
A virus inactivation method is provided. The method includes irradiating a solution containing an artificially expressed antibody or antibody fragment with ultraviolet rays in the presence of a radical scavenger. The irradiating only aggregates 5% or less of the antibody or antibody fragment. A wavelength of the ultraviolet rays is 200 nm or longer and 315 nm or shorter. An irradiation amount of the ultraviolet rays is 300 mJ/cm 2  or more. An irradiation time of the ultraviolet rays is 3 minutes or less. A concentration of the radical scavenger in the solution is 0.03 mM or more.
NEW MATERIAL:The macrocyclic polyamine of formula (n is 1-5) and a derivative of said polyamine wherein all or a part of the carboxyl groups are reduced to -CH2OH. USE:A ureterolithotriptic agent. It has excellent activity within the physiological pH range. It is infused as it is to the urinary tract or to the kidney with a pump to dissolve and remove the existing stones. PREPARATION:The compound of formula can be prepared, e.g. by reacting 1,4,7,10,13,16-hexaazacyclooctadecane with a halogenated organic acid such as chloroacetic acid, chlorobutyric acid, etc. in an aqueous solution of an alkali.
The present invention relates to compositions comprising polymers whose solubility characteristics can be changed by incubation and particularly poly (hydroxyalkyl(meth) acrylamide mono/di-lactate interpolymers. Another aspect of this invention is the application of such temperature sensitive polymers as release systems of biologically active compounds. The polymers of the present invention comprise monomers, which have modifiable functionality. The functionality of the monomers can for example be modified by the presence of hydrolysable groups. The modification is effected by the incubation, leading to a change of the water solubility characteristics of the polymer. The polymers used in the present invention contain hydrolysable chemical groups. As a result the polymer's solution characteristics, specifically its lower critical solution temperature (LCST), change upon incubation.
Impaired Liver Function

Do not use TAYTULLA in women with acute viral hepatitis or severe (decompensated) cirrhosis of liver [see Contraindications (4)]. Acute or chronic disturbances of liver function may necessitate the discontinuation of COC use until markers of liver function return to normal and COC causation has been excluded. Discontinue TAYTULLA if jaundice develops.

Liver Tumors

TAYTULLA is contraindicated in women with benign and malignant liver tumors [see Contraindications (4)]. Hepatic adenomas are associated with COC use. An estimate of the attributable risk is 3.3 cases per 100,000 COC users. Rupture of hepatic adenomas may cause death through intra-abdominal hemorrhage.

Studies have shown an increased risk of developing hepatocellular carcinoma in long-term (>8 years) COC users. However, the attributable risk of liver cancers in COC users is less than one case per million users.
Mesenchymal stem cell (MSC)-based therapy is an effective strategy for regenerative therapy. However, safety and ease of use are still issues to be overcome in clinical applications. Exosomes are naturally derived nanoparticles containing bioactive molecules, which serve as ideal cell-free therapeutic modalities. However, issues such as delivery, long-term preservation and activity maintenance of exosomes are other problems that limit their application. In this study, we proposed the use of rapid freeze-dry-thaw macroporous hydrogels for the encapsulation of HucMSC-derived exosomes (HucMSC-Exos) combined with an antimicrobial peptide coating. This exosome-encapsulated hyaluronic acid macroporous hydrogel HD-DP7/Exo can achieve long-term storage and transport by lyophilization and can be rapidly redissolved for treatment. After comprehensively comparing the therapeutic effects of HucMSC-Exos and HucMSC-loaded hydrogels, we found that HucMSC-Exos could also effectively regulate fibroblasts, vascular endothelial cells, and macrophages and inhibit myofibroblast-mediated fibrosis, thus promoting tissue regeneration and inhibiting scar formation in a mouse model of deep second-degree burn infection healing. These properties of lyophilized storage and whole-process-repair make HD-DP7/Exo have potential application value and application prospects.
All patients received induction phase 1 and phase2, followed by the protocol M, reinduction phase 1 and phase2, and maintenance (mercaptopurine 50 mg/m2 daily and methotrexate \[MTX\] 20 mg/m2 weekly, both orally) for up to a total therapy duration of 24 months. Response to treatment was evaluated on day 33 and at the end of induction in Modifed BFM-95.Sufficient response was defined as at least 70% tumor regression, less than 5% BM blasts, and no CNS disease on day 33 and complete remission detected by PET / CT at the end of induction.For patients with insufficient response at day 33 or at the end of induction treatment was to be intensified according to the high-risk branch of trial ALL-BFM95, with local radiotherapy (30 Gy) and allogeneic blood stem-cell transplantation.
The aim of this study was to explore the relationship between in-stent neoatherosclerosis (ISNA) and the neutrophil-to-lymphocyte ratio (NLR) in patients with in-stent restenosis (ISR) following drug-eluting stent (DES) implantation. We divided 216 patients into 3 groups based on the NLR tertile. We performed a comparative analysis of baseline, angiographic, and features of optical coherence tomography (OCT) between the NLR groups and performed univariate and multivariate logistic regression analyses to assess the association of the NLR with ISNA and in-stent thin-cap fibroatheroma (TCFA). Patients in the third tertile NLR group had a higher incidence of ISNA and in-stent TCFA compared with those in the first tertile. Multivariate logistic regression analysis showed that the hazard ratios and 95% confidence intervals for ISNA and TCFA were 2.673 (1.257-5.684; P = 0.038) and 4.272 (1.740-10.488; P = 0.004), respectively, for patients in the highest tertile compared with those in the lowest tertile. Our study showed that an increased NLR was associated with ISNA and in-stent plaque fragility in patients with ISR following DES implantation.
PROBLEM TO BE SOLVED: To provide a pharmaceutical composition for treating neurological disorders caused by Alzheimer's disease, central nervous system traumatic diseases, and an inflammatory component.SOLUTION: The pharmaceutical composition containing an effective amount of an active component comprising docosahexaenoic acid is provided. Oral administration is preferable as an administration route. Preferably, the effective amount for the treatment per day is about 10 mg/kg. It is preferable that solid form preparations and liquid form preparations or the like as the pharmaceutical composition. As the solid form preparations, powders, tablets, pills, capsules, granules, dispersible granules or the like are preferable. As a liquid form preparations, solutions, suspensions, and emulsions or the like are preferable.
Centrally inserted central catheters (CICC) are commonly used in the intensive care unit (ICU) for delivery of fluids, medications, and nutrition. They are also used to measure central venous pressure (CVP) which provides critical information about blood volume status and cardiac function of a patient. Currently, CICCs are the gold standard for measuring CVP, but they have a number of associated risks including pneumothorax, major hemorrhage, neck hematoma, and carotid puncture. An alternative to a CICC is a peripherally inserted central catheter (PICC). A PICC can be placed with lower risks than a CICC, has a lower rate of bloodstream infections, and provides longer-term IV access at a lower cost. PICCs can be used to deliver fluids, medications, and nutrition. However, there is minimal evidence that a PICC can measure CVP as effectively as a CICC. Therefore, a CICC is preferred when a patient requires CVP monitoring in our ICU. Our aim is to compare CVP measurements from CICCs and PICCs. We will also evaluate whether or not the duration of CICC placement affects the differences in CVP measurements between the CICCs and PICCs. We hypothesize that the differences between the CVP measurements of the CICCs and PICCs will be clinically insignificant.

The goal of this study is to determine if the central venous pressure (CVP) measurements obtained from a peripherally inserted central catheter (PICC) consistently correlate with the CVP measurements obtained from a centrally inserted central catheter (CICC). If the difference between the CVP measurements from the CICC and PICC are found to be clinically insignificant, then it may be practical to place PICCs in favor of CICCs thereby avoiding some of the potential complications associated with CICC placement. We also aim to evaluate whether or not the duration of CICC placement affects the differences in CVP measurements between the CICCs and PICCs. We hypothesize that the differences between the CVP measurements of the CICCs and PICCs will be clinically insignificant.
Patients receive WOKVAC ID on day 13. Treatment repeats for up to 3 cycles in the absence of disease progression or unacceptable toxicity. Patients also receive paclitaxel via infusion on days 1, 8, and 15, and trastuzumab IV and pertuzumab IV on day 1. Treatment repeats for up to 4 cycles in the absence of disease progression or unacceptable toxicity.
An 11 week (introduction plus 10 week) manualized treatment protocol focusing on parent psychoeducation and child socialization in children 4 to 7 years of age with social anxiety disorder and/or selective mutism. Parent and child groups run separately but concurrently.
Somatostatin analogues of formula (I) and their acid addition salts are new. (where R is H, an aminoacid or a dipeptide e.g. Ala-Gly; X1 is (L) Phe, (D) Ala or bond; X2 is (L)Phe, (D) Phe or Gly; X3 is (L) Phe, (D) Phe or a bond and the Cys groups have (L) or (D) configuration). (I) regulate the secretion of insulin, glucagon and growth hormone (GH) and may be used to regulate glycemic levels in insulin dependent and non-insulin dependent diabetes and to control acromegalia. Due to the (D) aminoacids, (I) have better resistance to proteolysis than somatostatin and have prolonged activity. (I) have little action on secretion of gastric juices and low toxicity. The activity profile of the pcds. differ from that of somatostatin and suitable cpds. may be selected for the required activity. (I) are administered as 1-5% solutions by intravenous, intramuscular or sub-cutaneous injection ot give doses of 0.1-10 mg.
BACKGROUND: MiRNAs are closely related to tumor radiosensitivity. MiR-378a-5p level is down-regulated in colorectal cancer (CRC). Therefore, this study intends to explore the role of miR-378a-5p in CRC, especially radiosensitivity.
METHODS: The expression of miR-378a-5p was analyzed in CRC samples. CRC cell lines were treated with different doses of X-rays. Bioinformatics analysis, dual-luciferase reporter assay and RT-qPCR were used to detect the expressions and binding relationship of miR-378a-5p and low-density lipoprotein receptor-related protein 8 (LRP8). MiR-378a-5p inhibitor or/and siLRP8 were transfected into CRC cells with or without irradiation. Subsequently, clonogenic assay, flow cytometry and in vivo experiments including tumorigenesis assay, immunohistochemistry, RT-qPCR and Western blot were performed to clarify the role of miR-378a-5p/LRP8 axis in the radiosensitivity of CRC.
RESULTS: The down-regulated expression of miR-378a-5p in CRC is related to histological differentiation and tumor-node-metastasis (TNM) stage. After irradiation, the survival fraction of CRC cells was decreased, while the apoptotic rate and the level of miR-378a-5p were increased. Restrained miR-378a-5p repressed apoptosis and apoptosis-related protein expressions, yet promoted the proliferation and the radioresistance of cells by regulating β-catenin in CRC cells. LRP8 was highly expressed in CRC, and targeted by miR-378a-5p. SiLRP8 improved radiosensitivity and reversed the effect of miR-378a-5p down-regulation on CRC cells. Overexpressed miR-378a-5p and irradiation enhanced the level of miR-378a-5p, yet suppressed the expressions of Ki67 and LRP8 as well as tumorigenesis.
CONCLUSION: MiR-378a-5p may exert a radiosensitizing effect on CRC through the LRP8/β-catenin axis, which may be a new therapeutic target for CRC radioresistance.
Experimental group: HILT + sham ultrasound therapy In the experimental group, participants received HILT treatment 1 session per day over a period of 2 consecutive weeks (5 days/week); total 10 sessions. In this study we used HIRO 3.0 device applied to the hemiplegic shoulder and the area of following muscles include upper trapezius, supraspinatus, deltoid, pectoralis minor muscles and the tender points. The treatment consisted of high peak power (3kW), a wavelength of 1064 nm. Two phases of treatment were performed according to Rotator cuff tendinopathy protocol of the device. The total energy administered will be approximately 2500 J. The total treatment time was approximately 10 minutes. They also received sham ultrasound therapy, which performed by applying probe with gel without turning on the device, for 10 minutes.
VONJO can cause prolongation of the QTc interval. QTc prolongation of >500 msec was higher in VONJO-treated patients than in patients in the control arm (1.4% vs 1%). QTc increase from baseline by 60 msec or higher was greater in VONJO-treated patients than in control arm patients (1.9% vs 1%). Adverse reactions of QTc prolongation were reported for 3.8% of VONJO-treated patients and 2% of control arm patients. No cases of torsades de pointes were reported.

Avoid use of VONJO in patients with a baseline QTc of >480 msec. Avoid use of drugs with significant potential for QTc prolongation in combination with VONJO. Correct hypokalemia prior to and during VONJO treatment.

Manage QTc prolongation using VONJO interruption and electrolyte management [see Dosage and Administration ( 2.5)] .